Issue: May 2016
May 05, 2016
3 min watch
Save

VIDEO: Novaliq announces full enrollment in phase 2 trial of dry eye treatment

Issue: May 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS — At the Ophthalmology Innovation Summit, Bernhard Günther, CEO of Novaliq, gives an update on the company portfolio, including news that it had completed enrollment in a phase 2 study of CyclASol for the treatment of moderate to severe dry eye disease.